# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

# B Applicant

Siemens Healthcare Diagnostics Inc.

# C Proprietary and Established Names

Atellica $\textsuperscript { \textregistered }$ IM High‑Sensitivity Troponin I (TnIH)

D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>MMI</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.1215 - CreatinePhosphokinase/Creatine Kinase OrIsoenzymes Test System</td><td rowspan=1 colspan=1>CH - Clinical Chemistry</td></tr></table>

# II Submission/Device Overview:

A Purpose for Submission:

Modification to the indications for use for the Atellica IM High-Sensitivity Troponin I (TnIH) assay cleared in K171566.

# B Measurand:

Cardiac troponin I (cTnI)

# C Type of Test:

Quantitative immunoassay

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

The Atellica $\textsuperscript { \textregistered }$ IM High‑Sensitivity Troponin I (TnIH) assay is for in vitro diagnostic use in the quantitative measurement of cardiac troponin I in human serum or plasma (lithium heparin) using the Atellica $\textsuperscript { \textregistered }$ IM Analyzer. The assay can be used to aid in the diagnosis of acute myocardial infarction (AMI).

The Atellica IM TnIH assay can be used as an aid in prognosis for 30-, 90-, 182-, and 365-day all-cause mortality (ACM) and major adverse cardiac events (MACE) in patients presenting with signs and symptoms suggestive of acute coronary syndrome (ACS). MACE consists of myocardial infarction, urgent revascularization, cardiac death, or heart failure hospitalization.

C Special Conditions for Use Statement(s): Rx - For Prescription Use Only For in vitro diagnostic use   
D Special Instrument Requirements: Atellica IM Analyzer

IV Device/System Characteristics:

A Device Description:

The Atellica IM High-Sensitivity Troponin I (TnIH) assay was described in K171566.

# B Principle of Operation:

The principle of operation for the Atellica IM High-Sensitivity Troponin I (TnIH) assay was described in K171566.

# V Substantial Equivalence Information:

A Predicate Device Name(s): VITROS Immunodiagnostic Products Troponin I ES Reagent Pack

B Predicate 510(k) Number(s): K062838

C Comparison with Predicate(s):   

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">Candidate DeviceK241165</td><td colspan="1" rowspan="1">Predicate DeviceK062838</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">Atellica® IM High-SensitivityTroponin I (TnIH)</td><td colspan="1" rowspan="1">VITROS ImmunodiagnosticProducts Troponin I ES ReagentPack</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicSimilarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indications ForUse</td><td colspan="1" rowspan="1">The assay can be used to aid inthe diagnosis of acute myocardialinfarction (AMI).</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">DetectionTechnology</td><td colspan="1" rowspan="1">Chemiluminescence</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Type ofImmunoassay</td><td colspan="1" rowspan="1">Sandwich Immunoassay</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Cardiac Troponin I</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicDifferences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indications ForUse</td><td colspan="1" rowspan="1">The assay can be used as an aid inprognosis for 30-, 90-, 182-, and365-day all-cause mortality(ACM) and major adverse cardiacevents (MACE) in patientspresenting with signs andsymptoms suggestive of acutecoronary syndrome (ACS).MACE consists of myocardialinfarction, urgentrevascularization, cardiac death,or heart failure hospitalization</td><td colspan="1" rowspan="1">For the quantitative measurementof cardiac Troponin I (cTnI) inhuman serum and plasma (heparinand EDTA) using the VITROSImmunodiagnostic System, to aidin the assessment of myocardialdamage and risk stratification.Aids in the risk stratification ofpatients with non-ST-segmentelevation acute coronarysyndromes with respect to relativerisk of mortality, myocardialinfarction (MI) or increasedprobability of ischemic eventsrequiring urgent revascularizationprocedures.</td></tr><tr><td colspan="1" rowspan="1">Specimen Type</td><td colspan="1" rowspan="1">Serum and lithium heparin plasma</td><td colspan="1" rowspan="1">Serum, lithium heparin plasma,and EDTA plasma</td></tr><tr><td colspan="1" rowspan="1">Measuring Range</td><td colspan="1" rowspan="1">2.5025,000.00 pg/mL</td><td colspan="1" rowspan="1">12-80,000 pg/mL</td></tr><tr><td colspan="1" rowspan="1">Upper 99thPercentile Cutoff</td><td colspan="1" rowspan="1">Lithium Heparin:Female: 34.11 pg/mLMale: 53.48 pg/mL</td><td colspan="1" rowspan="1">34 pg/mLAMI Diagnostic Cutoff 120pg/mL</td></tr><tr><td>Device &amp; Predicate Device(s):</td><td>Candidate Device K241165</td><td>Predicate Device K062838</td></tr><tr><td></td><td>Combined: 45.20 pg/mL Serum: Female: 38.64 pg/mL</td><td></td></tr><tr><td></td><td>Combined: 45.43 pg/mL Overall: 45.20 pg/mL</td><td></td></tr><tr><td>Calibration</td><td>2-point calibration</td><td>3 levels</td></tr></table>

# VI Standards/Guidance Documents Referenced:

Not Applicable

VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

The precision of the Atellica IM High-Sensitivity Troponin I (TnIH) assay was established in K171566.

2. Linearity:

The linearity of the Atellica IM High-Sensitivity Troponin I (TnIH) assay was established in K171566.

3. Analytical Specificity/Interference:

The analytical specificity/interference of the Atellica IM High-Sensitivity Troponin I (TnIH) assay was established in K171566.

4. Assay Reportable Range:

The reportable range of the Atellica IM High-Sensitivity Troponin I (TnIH) assay was established in K171566.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

The traceability, sample stability, and expected values of the Atellica IM High-Sensitivity Troponin I (TnIH) assay are unchanged since K171566.

6. Detection Limit:

The detection limit of the Atellica IM High-Sensitivity Troponin I (TnIH) assay was established in K171566.

# 7. Assay Cut-Off:

The assay cut-off of the Atellica IM High-Sensitivity Troponin I (TnIH) assay was established in K171566.

# B Comparison Studies:

1. Method Comparison with Predicate Device: Not applicable.

2. Matrix Comparison:

Not applicable. All performance studies in K171566 were performed in all applicable matrices (lithium heparin plasma and serum).

# C Clinical Studies:

1. Clinical Sensitivity:

The clinical sensitivity of the Atellica IM High-Sensitivity Troponin I (TnIH) assay as an aid in the diagnosis of AMI was established in K171566.

2. Clinical Specificity:

The clinical specificity of the Atellica IM High-Sensitivity Troponin I (TnIH) assay as an aid in the diagnosis of AMI was established in K171566.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):

A clinical study was performed to evaluate the prognostic performance of the device using the same clinical cohort described in K171566. Patients presenting to the emergency department with signs and symptoms suggestive of ACS were followed up for 30‑, 90‑, 182‑, and 365‑day progression to ACM and MACE (consisting of myocardial infarction, urgent revascularization, cardiac death, or heart failure hospitalization). At each time point, the risk (cumulative incidence) and hazard ratios were calculated for populations with baseline cardiac troponin I levels $\le \mathbf { o r } >$ the overall 99th percentile value. Lithium heparin plasma and serum specimens were collected and baseline cardiac troponin I levels were established using the Atellica IM Analyzer testing the first blood draw for each subject presenting to the emergency department. The median time of the first blood draw was 93 minutes after presentation to the emergency department.

Kaplan-Meier curves were generated to display the absolute risk (cumulative incidence) of ACM and MACE outcomes. Analyses were performed separately for both serum and lithium heparin plasma sample types using the overall 99th percentile value. Tables for pre- and posttest risk and unadjusted hazard ratios, adjusted hazard ratios (adjusted for prior revascularization, prior heart failure, estimated glomerular filtration rate (eGFR), hypertension and sex), multivariable Cox proportional hazards (PH) model parameters, and event types, as well as Kaplan-Meier curves, are presented for the following populations based on the overall 99th percentile value. Smoking, diabetes, Body Mass Index (BMI), race, and age were also evaluated and were not significantly associated with cumulative ACM/MACE for any cohort in this clinical population. Prior MI, statins, and depressed left ventricular ejection fraction (LVEF) were evaluated and removed from the model due to multicollinearity. The cohorts and results are summarized below.

• Cohort A: Study population excluding subjects with adjudicated AMI and only including subjects with prior history of MACE   
• Cohort B: Study population excluding subjects with adjudicated AMI and prior history of MACE   
• Cohort C: Study population excluding subjects with adjudicated AMI   
Cohort A (Study population excluding subjects with adjudicated AMI and only including   
subjects with prior history of MACE)   
Overall 99th percentile = 45.20 pg/mL for overall (both lithium heparin and serum samples for   
males and females combined

Pre‐ and Post‐Test Risk and Unadjusted Hazard Ratios   

<table><tr><td colspan="1" rowspan="2">Follow-UpTimePoints(Days)</td><td colspan="3" rowspan="1">Prevalence ofACM/MACE</td><td colspan="3" rowspan="1">Risk of ACM/MACE forpatients with cTnI levels&gt;99th Percentile</td><td colspan="3" rowspan="1">Risk of ACM/MACE forpatients with cTnI levels≤99th Percentile</td><td colspan="1" rowspan="2">UnadjustedHazardRatio(95% CI)</td></tr><tr><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">NumberofACM/MACEevents</td><td colspan="1" rowspan="1">Pre-testrisk ofACM/MACE(%)</td><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">NumberofACM/MACEevents</td><td colspan="1" rowspan="1">Post-test riskof ACM/MACE(%, 95% CI)</td><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">Numberof ACM/MACEevents</td><td colspan="1" rowspan="1">Post-testrisk ofACM/MACE(%, 95%CI)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="10" rowspan="1">Lithium Heparin</td></tr><tr><td colspan="1" rowspan="1">30Days</td><td colspan="1" rowspan="1">874</td><td colspan="1" rowspan="1">58</td><td colspan="1" rowspan="1">6.6</td><td colspan="1" rowspan="1">137</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">9.5(5.9, 14.8)</td><td colspan="1" rowspan="1">737</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">6.1(5.3, 7.0)</td><td colspan="1" rowspan="1">1.61(0.87, 2.98)</td></tr><tr><td colspan="1" rowspan="1">90Days</td><td colspan="1" rowspan="1">874</td><td colspan="1" rowspan="1">129</td><td colspan="1" rowspan="1">14.8</td><td colspan="1" rowspan="1">137</td><td colspan="1" rowspan="1">36</td><td colspan="1" rowspan="1">26.3(20.4, 33.2)</td><td colspan="1" rowspan="1">737</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">12.6(11.4, 13.9)</td><td colspan="1" rowspan="1">2.24(1.52, 3.29)</td></tr><tr><td colspan="1" rowspan="1">182Days</td><td colspan="1" rowspan="1">874</td><td colspan="1" rowspan="1">190</td><td colspan="1" rowspan="1">21.7</td><td colspan="1" rowspan="1">137</td><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">35.8(29.0, 43.2)</td><td colspan="1" rowspan="1">737</td><td colspan="1" rowspan="1">141</td><td colspan="1" rowspan="1">19.1(17.8, 20.5)</td><td colspan="1" rowspan="1">2.09(1.51, 2.90)</td></tr><tr><td colspan="1" rowspan="1">365Days</td><td colspan="1" rowspan="1">874</td><td colspan="1" rowspan="1">259</td><td colspan="1" rowspan="1">29.6</td><td colspan="1" rowspan="1">137</td><td colspan="1" rowspan="1">67</td><td colspan="1" rowspan="1">48.9(41.4, 56.4)</td><td colspan="1" rowspan="1">737</td><td colspan="1" rowspan="1">192</td><td colspan="1" rowspan="1">26.1(24.6, 27.6)</td><td colspan="1" rowspan="1">2.21(1.67, 2.92)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="3" rowspan="1"></td><td colspan="2" rowspan="1"></td><td colspan="5" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">30Days</td><td colspan="1" rowspan="1">883</td><td colspan="1" rowspan="1">60</td><td colspan="1" rowspan="1">6.8</td><td colspan="1" rowspan="1">131</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">10.7(6.8, 16.3)</td><td colspan="1" rowspan="1">752</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">6.1(5.3, 7.0)</td><td colspan="1" rowspan="1">1.82(1.00, 3.32)</td></tr><tr><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">NumberofACM/MACEevents</td><td colspan="1" rowspan="1">Pre-testrisk ofACM/MACE(%)</td><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">NumberofACM/MACEevents</td><td colspan="1" rowspan="1">Post-test riskof ACM/MACE(%, 95% CI)</td><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">Numberof ACM/MACEevents</td><td colspan="1" rowspan="1">Post-testrisk ofACM/MACE(%, 95%CI</td></tr><tr><td colspan="1" rowspan="1">90Days</td><td colspan="1" rowspan="1">883</td><td colspan="1" rowspan="1">129</td><td colspan="1" rowspan="1">14.6</td><td colspan="1" rowspan="1">131</td><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">26.7(20.2, 32.9)</td><td colspan="1" rowspan="1">752</td><td colspan="1" rowspan="1">94</td><td colspan="1" rowspan="1">12.5(11.3, 13.8)</td><td colspan="1" rowspan="1">2.31(1.57, 3.41)</td></tr><tr><td colspan="1" rowspan="1">182Days</td><td colspan="1" rowspan="1">883</td><td colspan="1" rowspan="1">192</td><td colspan="1" rowspan="1">21.7</td><td colspan="1" rowspan="1">131</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">36.6(29.0, 43.2)</td><td colspan="1" rowspan="1">752</td><td colspan="1" rowspan="1">144</td><td colspan="1" rowspan="1">19.1(17.8, 20.5)</td><td colspan="1" rowspan="1">2.16(1.56, 3.00)</td></tr><tr><td colspan="1" rowspan="1">365Days</td><td colspan="1" rowspan="1">883</td><td colspan="1" rowspan="1">262</td><td colspan="1" rowspan="1">29.7</td><td colspan="1" rowspan="1">131</td><td colspan="1" rowspan="1">65</td><td colspan="1" rowspan="1">49.6(41.5, 56.5)</td><td colspan="1" rowspan="1">752</td><td colspan="1" rowspan="1">197</td><td colspan="1" rowspan="1">26.2(24.6, 27.6)</td><td colspan="1" rowspan="1">2.25(1.70, 2.98)</td></tr></table>

Adjusted Hazard Ratios   

<table><tr><td rowspan=1 colspan=1>SampleMatrix</td><td rowspan=1 colspan=1>TimePoint</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>AdjustedHazard Ratio(95% CI)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SampleMatrix</td><td rowspan=1 colspan=1>TimePoint</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>AdjustedHazard Ratio(95% CI)</td></tr><tr><td rowspan=4 colspan=1>LithiumHeparinPlasma</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>799</td><td rowspan=1 colspan=1>1.07 (0.54, 2.09)</td><td rowspan=4 colspan=1></td><td rowspan=4 colspan=1>Serum</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>807</td><td rowspan=1 colspan=1>1.31 (0.68, 2.52)</td></tr><tr><td rowspan=1 colspan=1>90 Days</td><td rowspan=1 colspan=1>799</td><td rowspan=1 colspan=1>1.61 (1.06, 2.45)</td><td rowspan=1 colspan=1>90 Days</td><td rowspan=1 colspan=1>807</td><td rowspan=1 colspan=1>1.79 (1.18, 2.71)</td></tr><tr><td rowspan=1 colspan=1>182 Days</td><td rowspan=1 colspan=1>799</td><td rowspan=1 colspan=1>1.59 (1.12, 2.26)</td><td rowspan=1 colspan=1>182 Days</td><td rowspan=1 colspan=1>807</td><td rowspan=1 colspan=1>1.76 (1.24, 2.49)</td></tr><tr><td rowspan=1 colspan=1>365 Days</td><td rowspan=1 colspan=1>799</td><td rowspan=1 colspan=1>1.56 (1.15, 2.12)</td><td rowspan=1 colspan=1>365 Days</td><td rowspan=1 colspan=1>807</td><td rowspan=1 colspan=1>1.70 (1.25, 2.30)</td></tr></table>

Summary of Multivariable Cox PH Model Parameters   

<table><tr><td colspan="1" rowspan="1"></td><td colspan="6" rowspan="1">Adjusted hazard ratios (95% CI)</td></tr><tr><td colspan="1" rowspan="1">Follow-Up TimePoint</td><td colspan="1" rowspan="1">Troponin I</td><td colspan="1" rowspan="1">PriorRevascularization</td><td colspan="1" rowspan="1">PriorHeartFailure</td><td colspan="1" rowspan="1">eGFR</td><td colspan="1" rowspan="1">Hypertension</td><td colspan="1" rowspan="1">Sex</td></tr><tr><td colspan="7" rowspan="1">Lithium Heparin</td></tr><tr><td colspan="1" rowspan="1">30 days</td><td colspan="1" rowspan="1">1.07(0.54, 2.09)</td><td colspan="1" rowspan="1">0.64(0.36, 1.12)</td><td colspan="1" rowspan="1">1.76(0.96, 3.22)</td><td colspan="1" rowspan="1">1.59(0.91, 2.79)</td><td colspan="1" rowspan="1">1.16(0.49, 2.73)</td><td colspan="1" rowspan="1">1.62(0.89, 2.96)</td></tr><tr><td colspan="1" rowspan="1">90 days</td><td colspan="1" rowspan="1">1.61(1.06, 2.45)</td><td colspan="1" rowspan="1">0.82(0.56, 1.19)</td><td colspan="1" rowspan="1">2.20(1.45, 3.32)</td><td colspan="1" rowspan="1">1.52(1.05, 2.22)</td><td colspan="1" rowspan="1">1.57(0.82, 3.01)</td><td colspan="1" rowspan="1">1.42(0.96, 2.11)</td></tr><tr><td colspan="1" rowspan="1">182 days</td><td colspan="1" rowspan="1">1.59(1.12, 2.26)</td><td colspan="1" rowspan="1">0.91(0.67, 1.24)</td><td colspan="1" rowspan="1">2.19(1.57, 3.04)</td><td colspan="1" rowspan="1">1.41(1.03, 1.92)</td><td colspan="1" rowspan="1">1.61(0.95, 2.74)</td><td colspan="1" rowspan="1">1.28(0.93, 1.75)</td></tr><tr><td colspan="1" rowspan="1">365 days</td><td colspan="1" rowspan="1">1.56(1.15, 2.12)</td><td colspan="1" rowspan="1">0.91(0.70, 1.19)</td><td colspan="1" rowspan="1">2.23(1.68, 2.97)</td><td colspan="1" rowspan="1">1.50(1.15, 1.96)</td><td colspan="1" rowspan="1">1.54(0.98, 2.42)</td><td colspan="1" rowspan="1">1.28(0.98, 1.68)</td></tr><tr><td colspan="7" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">30 days</td><td colspan="1" rowspan="1">1.31(0.68, 2.52)</td><td colspan="1" rowspan="1">0.62(0.36, 1.08)</td><td colspan="1" rowspan="1">1.44(0.81, 2.57)</td><td colspan="1" rowspan="1">1.51(0.86, 2.63)</td><td colspan="1" rowspan="1">1.20(0.51, 2.81)</td><td colspan="1" rowspan="1">1.62(0.89, 2.94)</td></tr><tr><td colspan="1" rowspan="1">90 days</td><td colspan="1" rowspan="1">1.79(1.18, 2.71)</td><td colspan="1" rowspan="1">0.83(0.57, 1.21)</td><td colspan="1" rowspan="1">1.96(1.31, 2.94)</td><td colspan="1" rowspan="1">1.53(1.05, 2.22)</td><td colspan="1" rowspan="1">1.54(0.81, 2.96)</td><td colspan="1" rowspan="1">1.37(0.92, 2.02)</td></tr><tr><td colspan="1" rowspan="1">182 days</td><td colspan="1" rowspan="1">1.76(1.24, 2.49)</td><td colspan="1" rowspan="1">0.95(0.70, 1.29)</td><td colspan="1" rowspan="1">2.16(1.56, 2.99)</td><td colspan="1" rowspan="1">1.36(1.00, 1.85)</td><td colspan="1" rowspan="1">1.60(0.94, 2.71)</td><td colspan="1" rowspan="1">1.28(0.94, 1.75)</td></tr><tr><td colspan="1" rowspan="1">365 days</td><td colspan="1" rowspan="1">1.70(1.25, 2.30)</td><td colspan="1" rowspan="1">0.95(0.73, 1.24)</td><td colspan="1" rowspan="1">2.19(1.65, 2.91)</td><td colspan="1" rowspan="1">1.48(1.13, 1.93)</td><td colspan="1" rowspan="1">1.53(0.98, 2.40)</td><td colspan="1" rowspan="1">1.25(0.96, 1.64)</td></tr></table>

# Kaplan Meier Failure Plot

![](images/cb5adf762a18d82172434882628cfe2416140f6234bc38a834eb7180a57fe47b.jpg)

Event Types Summary (Lithium Heparin Plasma)   

<table><tr><td colspan="1" rowspan="1">Type of Event</td><td colspan="1" rowspan="1">Total,N=874 (%)</td><td colspan="1" rowspan="1">≤99thPercentile,N=737 (%)</td><td colspan="1" rowspan="1">&gt;99thPercentile,N=137 (%)</td></tr><tr><td colspan="1" rowspan="1">Survived to day 365 with no ACM/MACE</td><td colspan="1" rowspan="1">606</td><td colspan="1" rowspan="1">537</td><td colspan="1" rowspan="1">69</td></tr><tr><td colspan="1" rowspan="1">Loss to follow up</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">ACM/MACE</td><td colspan="1" rowspan="1">259</td><td colspan="1" rowspan="1">192</td><td colspan="1" rowspan="1">67</td></tr><tr><td colspan="4" rowspan="1">Breakdown of ACM/MACE event</td></tr><tr><td colspan="1" rowspan="1">Cardiac Death</td><td colspan="1" rowspan="1">10 (3.86)</td><td colspan="1" rowspan="1">9 (4.69)</td><td colspan="1" rowspan="1">1 (1.49)</td></tr><tr><td colspan="1" rowspan="1">Heart Failure Hospitalization</td><td colspan="1" rowspan="1">163 (62.93)</td><td colspan="1" rowspan="1">113 (58.85)</td><td colspan="1" rowspan="1">50 (74.63)</td></tr><tr><td colspan="1" rowspan="1">Incident Death</td><td colspan="1" rowspan="1">8 (3.09)</td><td colspan="1" rowspan="1">5 (2.60)</td><td colspan="1" rowspan="1">3 (4.48)</td></tr><tr><td colspan="1" rowspan="1">Myocardial Infarction</td><td colspan="1" rowspan="1">17 (6.56)</td><td colspan="1" rowspan="1">13 (6.77)</td><td colspan="1" rowspan="1">4 (5.97)</td></tr><tr><td colspan="1" rowspan="1">Myocardial Infarction, Heart FailureHospitalization</td><td colspan="1" rowspan="1">2 (0.77)</td><td colspan="1" rowspan="1">1 (0.52)</td><td colspan="1" rowspan="1">1 (1.49)</td></tr><tr><td colspan="1" rowspan="1">Myocardial Infarction, Urgent Revascularization</td><td colspan="1" rowspan="1">7 (2.70)</td><td colspan="1" rowspan="1">7 (3.65)</td><td colspan="1" rowspan="1">0 (0.00)</td></tr><tr><td colspan="1" rowspan="1">Myocardial Infarction, Urgent Revascularization,Heart Failure Hospitalization</td><td colspan="1" rowspan="1">1 (0.39)</td><td colspan="1" rowspan="1">1 (0.52)</td><td colspan="1" rowspan="1">0 (0.00)</td></tr><tr><td colspan="1" rowspan="1">Other Death</td><td colspan="1" rowspan="1">26 (10.04)</td><td colspan="1" rowspan="1">19 (9.90)</td><td colspan="1" rowspan="1">7 (10.45)</td></tr><tr><td colspan="1" rowspan="1">Urgent Revascularization</td><td colspan="1" rowspan="1">24 (9.27)</td><td colspan="1" rowspan="1">23 (11.98)</td><td colspan="1" rowspan="1">1 (1.49)</td></tr><tr><td colspan="1" rowspan="1">Urgent Revascularization, Heart FailureHospitalization</td><td colspan="1" rowspan="1">1 (0.39)</td><td colspan="1" rowspan="1">1 (0.52)</td><td colspan="1" rowspan="1">0 (0.00)</td></tr></table>

Cohort B (Study population excluding subjects with adjudicated AMI and prior history of   
MACE events)   
Overall 99th percentile $= 4 5 . 2 0 p g / m L$ for overall (both lithium heparin and serum samples for   
males and females combined)   
Cohort C (Study population excluding those with adjudicated AMI)   
Overall 99th percentile $= 4 5 . 2 0 p g / m L$ for overall (both lithium heparin and serum samples for   
males and females combined)

Pre‐ and Post‐Test Risk and Unadjusted Hazard Ratios   

<table><tr><td colspan="1" rowspan="2">Follow-UpTimePoints(Days)</td><td colspan="3" rowspan="1">Prevalence ofACM/MACE</td><td colspan="3" rowspan="1">Risk of ACM/MACE forpatients with cTnI levels&gt;99th Percentile</td><td colspan="3" rowspan="1">Risk of ACM/MACE forpatients with cTnI levels≤99th Percentile</td><td colspan="1" rowspan="2">UnadjustedHazard Ratio(95% CI)</td></tr><tr><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">NumberofACM/MACEevents</td><td colspan="1" rowspan="1">Pre-testrisk ofACM/MACE(%)</td><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">NumberofACM/MACEevents</td><td colspan="1" rowspan="1">Post-test riskof ACM/MACE(%, 95% CI)</td><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">Numberof ACM/MACEevents</td><td colspan="1" rowspan="1">Post-testrisk ofACM/MACE(%, 95%CI)</td></tr><tr><td colspan="11" rowspan="1">Lithium Heparin</td></tr><tr><td colspan="1" rowspan="1">30Days</td><td colspan="1" rowspan="1">1190</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">53</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">5.7(2.2, 13.6)</td><td colspan="1" rowspan="1">1137</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">0.5(0.3, 0.8)</td><td colspan="1" rowspan="1">10.89(2.72, 43.53)</td></tr><tr><td colspan="1" rowspan="1">90Days</td><td colspan="1" rowspan="1">1190</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">53</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">7.5(3.2, 16.7)</td><td colspan="1" rowspan="1">1137</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">1.1(0.9, 1.5)</td><td colspan="1" rowspan="1">6.84(2.23, 20.98)</td></tr><tr><td colspan="1" rowspan="1">182Days</td><td colspan="1" rowspan="1">1190</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">3.1</td><td colspan="1" rowspan="1">53</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">13.2(6.9, 23.9)</td><td colspan="1" rowspan="1">1137</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">2.6(2.3, 3.1)</td><td colspan="1" rowspan="1">5.28(2.32, 12.02)</td></tr><tr><td colspan="1" rowspan="1">365Days</td><td colspan="1" rowspan="1">1190</td><td colspan="1" rowspan="1">58</td><td colspan="1" rowspan="1">4.9</td><td colspan="1" rowspan="1">53</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">15.1(8.1, 26.4)</td><td colspan="1" rowspan="1">1137</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">4.4(4.0, 4.9)</td><td colspan="1" rowspan="1">3.69(1.75, 7.79)</td></tr><tr><td colspan="11" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">30Days</td><td colspan="1" rowspan="1">1214</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">57</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">3.5(1.0, 11.4)</td><td colspan="1" rowspan="1">1157</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">0.7(0.5, 0.9)</td><td colspan="1" rowspan="1">5.08(1.08, 23.94)</td></tr><tr><td colspan="1" rowspan="1">90Days</td><td colspan="1" rowspan="1">1214</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">57</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">5.3(1.9, 13.9)</td><td colspan="1" rowspan="1">1157</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">1.4(1.1, 1.7)</td><td colspan="1" rowspan="1">3.87(1.13, 13.28)</td></tr><tr><td colspan="1" rowspan="1">182Days</td><td colspan="1" rowspan="1">1214</td><td colspan="1" rowspan="1">39</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">57</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">10.5(5.1, 20.5)</td><td colspan="1" rowspan="1">1157</td><td colspan="1" rowspan="1">33</td><td colspan="1" rowspan="1">2.9(2.5, 3.2)</td><td colspan="1" rowspan="1">3.80(1.59, 9.07)</td></tr><tr><td colspan="1" rowspan="1">365Days</td><td colspan="1" rowspan="1">1214</td><td colspan="1" rowspan="1">61</td><td colspan="1" rowspan="1">5.0</td><td colspan="1" rowspan="1">57</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">12.3(6.2, 22.8)</td><td colspan="1" rowspan="1">1157</td><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">4.7(4.3, 5.1)</td><td colspan="1" rowspan="1">2.75(1.25, 6.05)</td></tr></table>

Adjusted Hazard Ratios   

<table><tr><td rowspan=1 colspan=1>SampleMatrix</td><td rowspan=1 colspan=1>TimePoint</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>AdjustedHazard Ratio(95% CI)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SampleMatrix</td><td rowspan=1 colspan=1>TimePoint</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Adjusted HazardRatio (95% CI)</td></tr><tr><td rowspan=4 colspan=1>LithiumHeparinPlasma</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>1169</td><td rowspan=1 colspan=1>7.46 (1.65, 33.65)</td><td rowspan=4 colspan=1></td><td rowspan=4 colspan=1>Serum</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>1192</td><td rowspan=1 colspan=1>2.84 (0.56, 14.38)</td></tr><tr><td rowspan=1 colspan=1>90 Days</td><td rowspan=1 colspan=1>1169</td><td rowspan=1 colspan=1>5.58 (1.69, 18.47)</td><td rowspan=1 colspan=1>90 Days</td><td rowspan=1 colspan=1>1192</td><td rowspan=1 colspan=1>2.81 (0.78,,10.12)</td></tr><tr><td rowspan=1 colspan=1>182 Days</td><td rowspan=1 colspan=1>1169</td><td rowspan=1 colspan=1>3.89 (1.63, 9.30)</td><td rowspan=1 colspan=1>182 Days</td><td rowspan=1 colspan=1>1192</td><td rowspan=1 colspan=1>2.71 (1.10, 6.69)</td></tr><tr><td rowspan=1 colspan=1>365 Days</td><td rowspan=1 colspan=1>1169</td><td rowspan=1 colspan=1>2.79 (1.28,,6.08)</td><td rowspan=1 colspan=1>365 Days</td><td rowspan=1 colspan=1>1192</td><td rowspan=1 colspan=1>2.06 (0.92, 4.64)</td></tr></table>

Summary of Multivariable Cox PH Model Parameters   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Adjusted hazard ratios (95% CI)</td></tr><tr><td rowspan=1 colspan=1>Follow-UpTime Point</td><td rowspan=1 colspan=1>Troponin I</td><td rowspan=1 colspan=1>eGFR</td><td rowspan=1 colspan=1>Hypertension</td><td rowspan=1 colspan=1>Sex</td></tr><tr><td rowspan=1 colspan=5>Lithium Heparin</td></tr><tr><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>7.46(1.65, 33.65)</td><td rowspan=1 colspan=1>2.16(0.46, 10.08)</td><td rowspan=1 colspan=1>2.07(0.41, 10.54)</td><td rowspan=1 colspan=1>1.32(0.35, 4.94)</td></tr><tr><td rowspan=1 colspan=1>90 days</td><td rowspan=1 colspan=1>5.58(1.69, 18.47)</td><td rowspan=1 colspan=1>1.73(0.51, 5.92)</td><td rowspan=1 colspan=1>1.21(0.43, 3.41)</td><td rowspan=1 colspan=1>1.52(0.58, 4.02)</td></tr><tr><td rowspan=1 colspan=1>182 days</td><td rowspan=1 colspan=1>3.89(1.63, 9.30)</td><td rowspan=1 colspan=1>2.41(1.09, 5.33)</td><td rowspan=1 colspan=1>1.18(0.58, 2.40)</td><td rowspan=1 colspan=1>1.56(0.81, 3.00)</td></tr><tr><td rowspan=1 colspan=1>365 days</td><td rowspan=1 colspan=1>2.79(1.28, 6.08)</td><td rowspan=1 colspan=1>2.30(1.21, 4.40)</td><td rowspan=1 colspan=1>1.20(0.69, 2.09)</td><td rowspan=1 colspan=1>1.53(0.90, 2.58)</td></tr><tr><td rowspan=1 colspan=5>Serum</td></tr><tr><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>2.84(0.56, 14.38)</td><td rowspan=1 colspan=1>4.05(1.05, 15.68)</td><td rowspan=1 colspan=1>2.28(0.46, 11.30)</td><td rowspan=1 colspan=1>1.52(0.43, 5.40)</td></tr><tr><td rowspan=1 colspan=1>90 days</td><td rowspan=1 colspan=1>2.81(0.78, 10.12)</td><td rowspan=1 colspan=1>2.49(0.84, 7.38)</td><td rowspan=1 colspan=1>1.41(0.52, 3.85)</td><td rowspan=1 colspan=1>1.43(0.57, 3.57)</td></tr><tr><td rowspan=1 colspan=1>182 days</td><td rowspan=1 colspan=1>2.71(1.10, 6.69)</td><td rowspan=1 colspan=1>2.89(1.37, 6.08)</td><td rowspan=1 colspan=1>1.26(0.63, 2.53)</td><td rowspan=1 colspan=1>1.49(0.78, 2.82)</td></tr><tr><td rowspan=1 colspan=1>365 days</td><td rowspan=1 colspan=1>2.06(0.92, 4.64)</td><td rowspan=1 colspan=1>2.61(1.41, 4.84)</td><td rowspan=1 colspan=1>1.19(0.69, 2.05)</td><td rowspan=1 colspan=1>1.52(0.91, 2.53)</td></tr></table>

![](images/8cc5efe34a045ff57476848ad3bdea941e819d6a53e2a081141a290834b98460.jpg)

Event Types Summary (Lithium Heparin Plasma)   

<table><tr><td rowspan=1 colspan=1>Type of Event</td><td rowspan=1 colspan=1>Total,N=1190 (%)</td><td rowspan=1 colspan=1>≤99thpercentile,N=1137 (%)</td><td rowspan=1 colspan=1>&gt;99thpercentile,N=53 (%)</td></tr><tr><td rowspan=1 colspan=1>Survived to day 365 with no ACM/MACE</td><td rowspan=1 colspan=1>1118</td><td rowspan=1 colspan=1>1073</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>Loss to follow up</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>ACM/MACE</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=4>Breakdown of ACM/MACE Event</td></tr><tr><td rowspan=1 colspan=1>Cardiac Death</td><td rowspan=1 colspan=1>2 (3.45)</td><td rowspan=1 colspan=1>2 (4.00)</td><td rowspan=1 colspan=1>0 (0.00)</td></tr><tr><td rowspan=1 colspan=1>Heart Failure Hospitalization</td><td rowspan=1 colspan=1>29 (50.00)</td><td rowspan=1 colspan=1>23 (46.00)</td><td rowspan=1 colspan=1>6 (75.00)</td></tr><tr><td rowspan=1 colspan=1>Myocardial Infarction</td><td rowspan=1 colspan=1>4 (6.90)</td><td rowspan=1 colspan=1>3 (6.00)</td><td rowspan=1 colspan=1>1 (12.50)</td></tr><tr><td rowspan=1 colspan=1>Myocardial Infarction, UrgentRevascularization, Cardiac Death</td><td rowspan=1 colspan=1>1 (1.72)</td><td rowspan=1 colspan=1>0 (0.00)</td><td rowspan=1 colspan=1>1 (12.50)</td></tr><tr><td rowspan=1 colspan=1>Other Death</td><td rowspan=1 colspan=1>14 (24.14)</td><td rowspan=1 colspan=1>14 (28.00)</td><td rowspan=1 colspan=1>0 (0.00)</td></tr><tr><td rowspan=1 colspan=1>Urgent Revascularization</td><td rowspan=1 colspan=1>8 (13.79)</td><td rowspan=1 colspan=1>8 (16.00)</td><td rowspan=1 colspan=1>0 (0.00)</td></tr></table>

Pre‐ and Post‐Test Risk and Unadjusted Hazard Ratios   

<table><tr><td rowspan=2 colspan=1>Follow-UpTimePoints(Days)</td><td rowspan=1 colspan=3>Prevalence ofACM/MACE</td><td rowspan=1 colspan=3>Risk of ACM/MACE forpatients with cTnI levels&gt;99th Percentile</td><td rowspan=1 colspan=3>Risk of ACM/MACE forpatients with cTnI levels≤99th Percentile</td><td rowspan=2 colspan=1>UnadjustedHazardRatio(95% CI)</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>NumberofACM/MACEevents</td><td rowspan=1 colspan=1>Pre-testrisk ofACM/MACE(%)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>NumberofACM/MACEevents</td><td rowspan=1 colspan=1>Post-test riskof ACM/MACE(%, 95% CI)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Numberof ACM/MACEevents</td><td rowspan=1 colspan=1>Post-testrisk ofACM/MACE(%, 95%CI</td></tr><tr><td rowspan=1 colspan=11>Lithium Heparin</td></tr><tr><td rowspan=1 colspan=1>30Days</td><td rowspan=1 colspan=1>2064</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>190</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>8.4(5.5, 12.6)</td><td rowspan=1 colspan=1>1874</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>2.7(2.4, 3.1)</td><td rowspan=1 colspan=1>3.21(1.83, 5.64)</td></tr><tr><td rowspan=1 colspan=1>90Days</td><td rowspan=1 colspan=1>2064</td><td rowspan=1 colspan=1>146</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>190</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>21.1(16.4, 26.6)</td><td rowspan=1 colspan=1>1874</td><td rowspan=1 colspan=1>106</td><td rowspan=1 colspan=1>5.7(5.1, 6.2)</td><td rowspan=1 colspan=1>4.03(2.80, 5.80)</td></tr><tr><td rowspan=1 colspan=1>182Days</td><td rowspan=1 colspan=1>2064</td><td rowspan=1 colspan=1>227</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>190</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>29.5(24.0, 35.6)</td><td rowspan=1 colspan=1>1874</td><td rowspan=1 colspan=1>171</td><td rowspan=1 colspan=1>9.1(8.5, 9.8)</td><td rowspan=1 colspan=1>3.66(2.71, 4.95)</td></tr><tr><td rowspan=1 colspan=1>365Days</td><td rowspan=1 colspan=1>2064</td><td rowspan=1 colspan=1>317</td><td rowspan=1 colspan=1>15.4</td><td rowspan=1 colspan=1>190</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>39.5(33.3, 46.0)</td><td rowspan=1 colspan=1>1874</td><td rowspan=1 colspan=1>242</td><td rowspan=1 colspan=1>12.9(12.2, 13.6)</td><td rowspan=1 colspan=1>3.64(2.81, 4.72)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>30Days</td><td rowspan=1 colspan=1>2097</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>8.5(5.6, 12.8)</td><td rowspan=1 colspan=1>1909</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>2.8(2.5, 3.2)</td><td rowspan=1 colspan=1>3.13(1.79, 5.47)</td></tr><tr><td rowspan=1 colspan=1>90Days</td><td rowspan=1 colspan=1>2097</td><td rowspan=1 colspan=1>148</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>20.2(15.6, 25.8)</td><td rowspan=1 colspan=1>1909</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>5.8(5.3, 6.3)</td><td rowspan=1 colspan=1>3.79(2.62, 5.48)</td></tr><tr><td rowspan=1 colspan=1>182Days</td><td rowspan=1 colspan=1>2097</td><td rowspan=1 colspan=1>231</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>28.7(23.3, 34.9)</td><td rowspan=1 colspan=1>1909</td><td rowspan=1 colspan=1>177</td><td rowspan=1 colspan=1>9.3(8.7, 9.9)</td><td rowspan=1 colspan=1>3.49(2.57, 4.74)</td></tr><tr><td rowspan=1 colspan=1>365Days</td><td rowspan=1 colspan=1>2097</td><td rowspan=1 colspan=1>323</td><td rowspan=1 colspan=1>15.4</td><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>38.3(32.2, 44.8)</td><td rowspan=1 colspan=1>1909</td><td rowspan=1 colspan=1>251</td><td rowspan=1 colspan=1>13.1(12.5, 13.8)</td><td rowspan=1 colspan=1>3.44(2.65, 4.47)</td></tr></table>

Adjusted Troponin I Hazard Ratios   

<table><tr><td rowspan=1 colspan=1>SampleMatrix</td><td rowspan=1 colspan=1>TimePoint</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>AdjustedHazard Ratio(95% CI)</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>SampleMatrix</td><td rowspan=1 colspan=1>TimePoint</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Adjusted HazardRatio (95% CI)</td></tr><tr><td rowspan=4 colspan=1>LithiumHeparinPlasma</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>1968</td><td rowspan=1 colspan=1>1.55 (0.84, 2.89)</td><td rowspan=1 colspan=2></td><td rowspan=4 colspan=1></td><td rowspan=4 colspan=1>Serum</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>1999</td></tr><tr><td rowspan=1 colspan=1>90 Days</td><td rowspan=1 colspan=1>1968</td><td rowspan=1 colspan=1>2.03 (1.36, 3.01)</td><td></td><td></td><td rowspan=1 colspan=1>90 Days</td><td rowspan=1 colspan=1>1999</td><td rowspan=1 colspan=1>2.11 (1.42, 3.13)</td></tr><tr><td rowspan=1 colspan=1>182 Days</td><td rowspan=1 colspan=1>1968</td><td rowspan=1 colspan=1>1.97 (1.42, 2.73)</td><td></td><td></td><td rowspan=1 colspan=1>182 Days</td><td rowspan=1 colspan=1>1999</td><td rowspan=1 colspan=1>2.04 (1.48, 2.83)</td></tr><tr><td rowspan=1 colspan=1>365 Days</td><td rowspan=1 colspan=1>1968</td><td rowspan=1 colspan=1>1.85 (1.39, 2.47)</td><td></td><td></td><td rowspan=1 colspan=1>365 Days</td><td rowspan=1 colspan=1>1999</td><td rowspan=1 colspan=1>1.91 (1.44, 2.54)</td></tr></table>

Summary of Multivariable Cox PH Model Parameters   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=6>Adjusted hazard ratios (95% CI)</td></tr><tr><td rowspan=1 colspan=1>Follow-Up TimePoint</td><td rowspan=1 colspan=1>Troponin I</td><td rowspan=1 colspan=1>PriorRevascularization</td><td rowspan=1 colspan=1>PriorHeartFailure</td><td rowspan=1 colspan=1>eGFR</td><td rowspan=1 colspan=1>Hypertension</td><td rowspan=1 colspan=1>Sex</td></tr><tr><td rowspan=1 colspan=7>Lithium Heparin</td></tr><tr><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>1.55(0.84, 2.89)</td><td rowspan=1 colspan=1>1.19(0.71, 2.02)</td><td rowspan=1 colspan=1>3.62(2.07, 6.33)</td><td rowspan=1 colspan=1>1.74(1.02, 2.98)</td><td rowspan=1 colspan=1>1.87(0.86, 4.05)</td><td rowspan=1 colspan=1>1.62(0.94, 2.79)</td></tr><tr><td rowspan=1 colspan=1>90 days</td><td rowspan=1 colspan=1>2.03(1.36, 3.01)</td><td rowspan=1 colspan=1>1.39(0.98, 1.97)</td><td rowspan=1 colspan=1>4.35(2.96, 6.38)</td><td rowspan=1 colspan=1>1.60(1.11, 2.29)</td><td rowspan=1 colspan=1>1.93(1.12, 3.31)</td><td rowspan=1 colspan=1>1.48(1.03, 2.14)</td></tr><tr><td rowspan=1 colspan=1>182 days</td><td rowspan=1 colspan=1>1.97(1.42, 2.73)</td><td rowspan=1 colspan=1>1.50(1.13, 1.98)</td><td rowspan=1 colspan=1>3.79(2.80, 5.12)</td><td rowspan=1 colspan=1>1.56(1.16, 2.08)</td><td rowspan=1 colspan=1>1.85(1.23, 2.80)</td><td rowspan=1 colspan=1>1.37(1.03, 1.82)</td></tr><tr><td rowspan=1 colspan=1>365 days</td><td rowspan=1 colspan=1>1.85(1.39, 2.47)</td><td rowspan=1 colspan=1>1.47(1.16, 1.88)</td><td rowspan=1 colspan=1>3.80(2.94, 4.92)</td><td rowspan=1 colspan=1>1.63(1.27, 2.10)</td><td rowspan=1 colspan=1>1.75(1.24, 2.45)</td><td rowspan=1 colspan=1>1.37(1.08, 1.74)</td></tr><tr><td rowspan=1 colspan=7>Serum</td></tr><tr><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>1.68(0.91, 3.09)</td><td rowspan=1 colspan=1>1.22(0.73, 2.03)</td><td rowspan=1 colspan=1>2.99(1.74, 5.13)</td><td rowspan=1 colspan=1>1.78(1.05, 3.02)</td><td rowspan=1 colspan=1>2.05(0.95, 4.41)</td><td rowspan=1 colspan=1>1.71(0.99, 2.92)</td></tr><tr><td rowspan=1 colspan=1>90 days</td><td rowspan=1 colspan=1>2.11(1.42, 3.13)</td><td rowspan=1 colspan=1>1.43(1.01, 2.03)</td><td rowspan=1 colspan=1>3.81(2.62, 5.55)</td><td rowspan=1 colspan=1>1.65(1.15, 2.36)</td><td rowspan=1 colspan=1>2.01(1.17, 3.44)</td><td rowspan=1 colspan=1>1.45(1.01, 2.07)</td></tr><tr><td rowspan=1 colspan=1>182 days</td><td rowspan=1 colspan=1>2.04(1.48, 2.83)</td><td rowspan=1 colspan=1>1.54(1.17, 2.03)</td><td rowspan=1 colspan=1>3.66(2.72, 4.92)</td><td rowspan=1 colspan=1>1.54(1.15, 2.06)</td><td rowspan=1 colspan=1>1.89(1.25, 2.85)</td><td rowspan=1 colspan=1>1.38(1.04, 1.83)</td></tr><tr><td rowspan=1 colspan=1>365 days</td><td rowspan=1 colspan=1>1.91(1.44, 2.54)</td><td rowspan=1 colspan=1>1.52(1.20, 1.93)</td><td rowspan=1 colspan=1>3.67(2.85, 4.73)</td><td rowspan=1 colspan=1>1.64(1.28, 2.10)</td><td rowspan=1 colspan=1>1.73(1.24, 2.42)</td><td rowspan=1 colspan=1>1.36(1.07, 1.73)</td></tr></table>

![](images/ad73a94d6211c05e20cbb55c177d5f7ba23f99ae7054091cfe5db49ecb8d2efa.jpg)  
Note: Error bars denote 95% confidence limits.

Event Types Summary (Lithium Heparin Plasma)   

<table><tr><td colspan="1" rowspan="1">Type of Event</td><td colspan="1" rowspan="1">Total,N=2064 (%)</td><td colspan="1" rowspan="1">≤99thpercentile,N=1874 (%)</td><td colspan="1" rowspan="1">&gt;99thpercentile,N=190 (%)</td></tr><tr><td colspan="1" rowspan="1">Survived to day 365 with noACM/MACE</td><td colspan="1" rowspan="1">1724</td><td colspan="1" rowspan="1">1610</td><td colspan="1" rowspan="1">114</td></tr><tr><td colspan="1" rowspan="1">Loss to follow up</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">ACM/MACE</td><td colspan="1" rowspan="1">317</td><td colspan="1" rowspan="1">242</td><td colspan="1" rowspan="1">75</td></tr><tr><td colspan="4" rowspan="1">Breakdown of ACM/MACE Event</td></tr><tr><td colspan="1" rowspan="1">Cardiac Death</td><td colspan="1" rowspan="1">12 (3.79)</td><td colspan="1" rowspan="1">11 (4.55)</td><td colspan="1" rowspan="1">1 (1.33)</td></tr><tr><td colspan="1" rowspan="1">Heart Failure Hospitalization</td><td colspan="1" rowspan="1">192 (60.57)</td><td colspan="1" rowspan="1">136 (56.20)</td><td colspan="1" rowspan="1">56 (74.67)</td></tr><tr><td colspan="1" rowspan="1">Incident Death</td><td colspan="1" rowspan="1">8 (2.52)</td><td colspan="1" rowspan="1">5 (2.07)</td><td colspan="1" rowspan="1">3 (4.00)</td></tr><tr><td colspan="1" rowspan="1">Myocardial Infarction</td><td colspan="1" rowspan="1">21 (6.62)</td><td colspan="1" rowspan="1">16 (6.61)</td><td colspan="1" rowspan="1">5 (6.67)</td></tr><tr><td colspan="1" rowspan="1">Myocardial Infarction, HeartFailure Hospitalization</td><td colspan="1" rowspan="1">2 (0.63)</td><td colspan="1" rowspan="1">1 (0.41)</td><td colspan="1" rowspan="1">1 (1.33)</td></tr><tr><td colspan="1" rowspan="1">Myocardial Infarction, UrgentRevascularization</td><td colspan="1" rowspan="1">7 (2.21)</td><td colspan="1" rowspan="1">7 (2.89)</td><td colspan="1" rowspan="1">0 (0.00)</td></tr><tr><td colspan="1" rowspan="1">Myocardial Infarction, UrgentRevascularization, CardiacDeath</td><td colspan="1" rowspan="1">1 (0.32)</td><td colspan="1" rowspan="1">0 (0.00)</td><td colspan="1" rowspan="1">1 (1.33)</td></tr><tr><td colspan="1" rowspan="1">Myocardial Infarction, UrgentRevascularization, Heart FailureHospitalization</td><td colspan="1" rowspan="1">1 (0.32)</td><td colspan="1" rowspan="1">1 (0.41)</td><td colspan="1" rowspan="1">0 (0.00)</td></tr><tr><td colspan="1" rowspan="1">Other Death</td><td colspan="1" rowspan="1">40 (12.62)</td><td colspan="1" rowspan="1">33 (13.64)</td><td colspan="1" rowspan="1">7 (9.33)</td></tr><tr><td colspan="1" rowspan="1">Urgent Revascularization</td><td colspan="1" rowspan="1">24 (10.09)</td><td colspan="1" rowspan="1">23 (12.81)</td><td colspan="1" rowspan="1">1 (1.33)</td></tr><tr><td colspan="1" rowspan="1">Urgent Revascularization, HeartFailure Hospitalization</td><td colspan="1" rowspan="1">1 (0.32)</td><td colspan="1" rowspan="1">1 (0.41)</td><td colspan="1" rowspan="1">0 (0.00)</td></tr></table>

# D Clinical Cut-Off:

The clinical cut-off of the Atellica IM High-Sensitivity Troponin I (TnIH) assay was established in K171566.

# E Expected Values/Reference Range:

The expected values/reference range of the Atellica IM High-Sensitivity Troponin I (TnIH) assay were established in K171566.

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.